MPM BIOVENTURES 2018, L.P. sold $1.9M of TRDA (indirect holdings)
MPM BIOVENTURES 2018, L.P. sold 259,837 indirectly-held shares of Entrada Therapeutics, Inc. (TRDA) at an average of $7.33 ($7.11–$7.41, $1.91M total) across 3 trades over 2026-09-04 to 2026-09-09. Filed jointly with MPM BioVentures 2018 LLC (10% owner) and MPM BioVentures 2018 GP LLC (10% owner).
How this was made
The 30-second read
Why it matters
The transaction is a primary disclosure but modest in size, offering limited trading insight.
Market read
Provides a small insider sell signal with limited market impact.
What to watch
Potential upcoming dilution or financing activities not disclosed.
Background
SEC Form 4 filing by a major insider showing a sale of shares.
Ticker impact
Form 4 disclosed MPM BioVentures sold ~1.9M shares of Entrada Therapeutics at $7.33 average price.
Potential slight downward pressure, likely limited.
Sale amount is under $2M and represents a small portion of holdings; market may view as routine.
Market effects
Minimal impact on biotech sector.
Negligible effect on US markets.
Low relevance globally.
Counterpoint
Sale could be strategic rebalancing rather than lack of confidence.
Key entities
- CompanyEntrada Therapeutics, Inc.
Biotech firm whose shares were sold.
- InvestorMPM BioVentures 2018, L.P.
Insider holder executing the sale.
